Description:
Epilepsy is one of the most common chronic neurological diseases worldwide. It is estimated that 1% of the world's population is affected by epilepsy during their lifetime with approximately 2.4 million new diagnosis being made each year. Although several anti-epileptic and anticonvulsant drugs are available for subscription, a significant number of patients continue to have seizures despite such treatment or are resistant to the medicaments.
The technology concerns a novel pharmaceutical composition that modulates the response of GABAA receptor with anticonvulsant activity. The pharmaceutical composition constitutes a scaffold for the development of a new class of medicaments for conditions like insomnia, anxiety, cardiac disease and/or epilepsy, and other processes where GABAA receptors are involved like pain, mood and panic disorders, schizophrenia and symptoms connected to alcohol and/or substance withdrawal/abuse.
Benefits:
- Development of novel pharmaceutical compositions with high affinity for specific GABAA receptor subtypes.
- Selective target of specific brain areas.
- Reduction of severe side effects that can occur.
- Non-complex synthesis.
Patent protection applied for.